Association of platelet to albumin ratio with metabolic dysfunction-associated steatotic liver disease based on the National Health and Nutrition Survey 2017-2018

被引:0
|
作者
Xie, Jiao [1 ]
He, Qingliu [2 ]
Fisher, David [3 ]
Pronyuk, Khrystyna [4 ]
Musabaev, Erkin [5 ]
Zhao, Lei [6 ]
机构
[1] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Hlth Management Ctr, Wuhan 430022, Peoples R China
[2] Fujian Med Univ, Dept Urol, Affiliated Hosp 2, Quanzhou 362000, Peoples R China
[3] Univ Western Cape, Fac Nat Sci, Dept Med Biosci, Cape Town, South Africa
[4] O Bogomolets Natl Med Univ, Infect Dis Dept, Kyiv, Ukraine
[5] Minist Hlth, Res Inst Virol, Tashkent 100122, Uzbekistan
[6] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Infect Dis, Wuhan 430022, Hubei, Peoples R China
来源
SCIENTIFIC REPORTS | 2025年 / 15卷 / 01期
基金
中国国家自然科学基金;
关键词
Metabolic dysfunction-associated steatotic liver disease; Steatosis; PAR; NHANES; PREOPERATIVE PLATELET; SERUM-ALBUMIN; INFLAMMATION;
D O I
10.1038/s41598-025-92837-5
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
The prevalence and incidence of metabolic dysfunction-associated steatotic liver disease (MASLD) are significantly increasing globally, but the index of non-invasive disease is limited. Platelet-albumin ratio(PAR) is a non-invasive biomarker of inflammation, the aim of this study was to evaluate the relationship between PAR and MASLD. This population-based cross-sectional retrospective study analyzed data extracted from the National Health and Nutrition Survey (NHANES) database from 2017 to 2018. Multivariate logistic regression analysis was used to evaluate the correlation between PAR and MASLD in different models. Model I was unadjusted, model II adjusted for race, sex and age, and model III was adjusted based on model II plus smoking status, hypertension, and diabetes. Further subgroup analysis was carried out according to sex, age, hypertension and diabetes status. The study involved 3287 participants, of whom 873 (26.5%) were diagnosed with MASLD. The PAR level in MASLD group was significantly higher than non-MASLD group (P < 0.05). Multivariate logistic regression revealed that high PAR level was an independent risk factor for MASLD (OR = 2.58, 95%CI: 1.26-5.27, P = 0.03), which adjusted for sex, age, race, smoking status, hypertension, and diabetes.The same results were observed in multiple subgroups of further subgroup analysis, and it can effectively predict the risk of MASLD (AUC = 0.842, 95% CI: 0.826-0.859). In conclusion, the new biomarker PAR shows a positive correlation with the risk of MASLD in the population, and can be used as a biomarker of MASLD to help clinicians identify people at high risk of MASLD.
引用
收藏
页数:10
相关论文
共 50 条
  • [41] A European Survey to Identify Challenges in the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease
    Castera, Laurent
    Alazawi, William
    Bugianesi, Elisabetta
    Caussy, Cyrielle
    Federici, Massimo
    Romero-Gomez, Manuel
    Schattenberg, Joern M.
    Basuroy, Ron
    Prasad, Preethy
    Estulin, Dmitry
    Lazarus, Jeffrey V.
    LIVER INTERNATIONAL, 2025, 45 (02)
  • [42] Natural history of metabolic dysfunction-associated steatotic liver disease
    Lekakis, Vasileios
    Papatheodoridis, George, V
    EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2024, 122 : 3 - 10
  • [43] Mechanism of PANoptosis in metabolic dysfunction-associated steatotic liver disease
    Ni, Keying
    Meng, Lina
    CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY, 2024, 48 (07)
  • [44] Vitamin E in Metabolic Dysfunction-Associated Steatotic Liver Disease
    Polyzos, Stergios A.
    Kountouras, Jannis
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2025, 40 (02) : 551 - 552
  • [45] Metabolic Dysfunction-Associated Steatotic Liver Disease: An Overview of Pharmacotherapy
    El Hussein, Mohamed
    Favell, Daniel
    JNP- THE JOURNAL FOR NURSE PRACTITIONERS, 2025, 21 (02):
  • [46] Sexual dimorphism of metabolic dysfunction-associated steatotic liver disease
    Cherubini, Alessandro
    Della Torre, Sara
    Pelusi, Serena
    Valenti, Luca
    TRENDS IN MOLECULAR MEDICINE, 2024, 30 (12) : 1126 - 1136
  • [47] Gut Microbiota and Metabolic Dysfunction-Associated Steatotic Liver Disease
    Scarpellini, Emidio
    Scarcella, Marialaura
    Tack, Jan F.
    Scarlata, Giuseppe Guido Maria
    Zanetti, Michela
    Abenavoli, Ludovico
    ANTIOXIDANTS, 2024, 13 (11)
  • [48] Hepatocellular Carcinoma in Metabolic Dysfunction-Associated Steatotic Liver Disease
    Rodriguez, Luis A.
    Schmittdiel, Julie A.
    Liu, Liyan
    Macdonald, Brock A.
    Balasubramanian, Sreepriya
    Chai, Krisna P.
    Seo, Suk I.
    Mukhtar, Nizar
    Levin, Theodore R.
    Saxena, Varun
    JAMA NETWORK OPEN, 2024, 7 (07) : e2421019
  • [49] Association between remnant cholesterol and metabolic dysfunction-associated steatotic liver disease in the elderly
    Lan, Yanqi
    Guo, Zhinan
    Dai, Junsheng
    Chen, Kailin
    Chen, Youlan
    DIGESTIVE AND LIVER DISEASE, 2024, 56 (09) : 1557 - 1564
  • [50] Metabolic dysfunction-associated steatotic liver disease and risk of cardiovascular disease
    Lee, Hyeok-Hee
    Lee, Han Ah
    Kim, Eun-Jin
    Kim, Hwi Young
    Kim, Hyeon Chang
    Ahn, Sang Hoon
    Lee, Hokyou
    Kim, Seung Up
    GUT, 2024, 73 (03) : 533 - 540